Shepherd, J., Brodin, H. (Håkan), Cave, C. (Carolyn), Waugh, Norman, Price, A. (Alison) and Gabbay, J. (John). (2004) Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C : a systematic review and economic evaluation. Health Technology Assessment, Vol.8 (No.39). ISSN 1366-5278

Preview	Text WRAP_Waugh_monhepCcombo.pdf - Published Version Download (538Kb) | Preview
Preview	Text (Cover sheet) WRAP_waugh4_Coversheet_FinalVersion.pdf Download (168Kb) | Preview

Abstract

Objectives: To assess the clinical-effectiveness and cost-effectiveness of pegylated interferon-α combined with ribavirin in the treatment of chronic hepatitis C. Data sources: Electronic databases, reference lists of retrieved reports, and the industry submissions to the National Institute for Clinical Excellence. Review methods: Sources were rigorously searched and studies were selected that met the inclusion criteria of being randomised controlled trials (RCTs) involving comparisons between pegylated interferon-α plus ribavirin and non-pegylated interferon plus ribavirin (two trials) or pegylated interferon alone and non-pegylated interferon alone (four trials). The primary outcome in all trials was sustained virological response (SVR) at follow-up. The trials were generally of good quality, although reporting of methodological details could have been more thorough in places. A cost-effectiveness model followed a hypothetical cohort of 1000 individuals with chronic hepatitis C over a 30-year period. Results: In the two trials that tested pegylated interferon plus ribavirin against non-pegylated interferon plus ribavirin the combined percentage of sustained virological response was 55%. The relative risk (RR) for remaining infected was reduced by 17% for pegylated interferon plus ribavirin compared with non-pegylated interferon plus ribavirin. Response to therapy varied according to viral genotype. Patients with genotype 1 had the lowest levels of sustained virological response and patients with genotype 2 or 3 had the highest. In the four trials that evaluated pegylated interferon monotherapy against non-pegylated interferon the combined sustained virological response rates were 31% for pegylated interferon and 14% for non-pegylated interferon. The RR for remaining infected with hepatitis C was reduced by 20% with the use of pegylated interferon. Patients with genotype 1 had the lowest levels of sustained virological response. There were also variations in sustained virological response according to other prognostic variables such as baseline viral load. Regimens involving pegylated interferon appear to be fairly well tolerated. Adverse events were been reported, but they did not differ substantially from levels of adverse events in regimens involving non-pegylated interferon. The incremental discounted cost per QALY for comparing no active treatment to 48 weeks of dual therapy with pegylated interferon and ribavirin (PEG + RBV) was £6045. When moving from 48 weeks of dual therapy with non-pegylated interferon and ribavirin (IFN + RBV) to 48 weeks of dual therapy with PEG + RBV the figure was £12,123. Subgroup analyses for dual PEG + RBV therapy demonstrated that the most favourable incremental discounted cost per QALY estimates were for patients infected with genotypes 2 and 3, and with low baseline viral load (£3921) compared with no active treatment. Results of one-way sensitivity analyses showed that the estimates varied according to differences in SVRs, drug costs and discount rates. In general estimates remained under £30,000 per QALY. The incremental discounted cost per QALY when moving from no active treatment to 48 weeks of monotherapy with pegylated interferon was £6484. When moving from 48 weeks of monotherapy with IFN to 48 weeks of monotherapy with PEG the figure was £8404. As with dual therapy, the lowest incremental cost per QALY was for patients with genotypes 2 and 3 and low baseline viral load, in the range £2641–4194. The highest estimates were for patients with genotype 1 and high baseline viral load, around £30,000. Conclusions: Well-designed RCTs show that patients treated with pegylated interferon, both as dual therapy and as monotherapy, experience higher sustained viral response rates than those treated with non-pegylated interferon. Patients with genotypes 2 and 3 experience the highest response, with rates in excess of 80%. Patients with the harder to treat genotype 1 nevertheless benefit, with up to 46% of patients experiencing an SVR in one of the trials. Pegylated interferon also appears to be relatively cost-effective in both monotherapy and dual therapy, with cost per QALY estimates remaining generally under £30,000. The most favourable estimates were for patients with genotypes 2 and 3. Pegylated interferon is a relatively new intervention in the treatment of hepatitis C and therefore there are areas where further research is needed. These include: efficacies of therapy with PEG-α-2a vs PEG-α-2b; retreatment of previous non-responders using pegylated interferon; efficacy of treatments and long-term outcomes in patients who have other co-morbidities; prospective tests of rules governing stopping treatment; treating patients with acute hepatitis C; problems that may occur in a minority of patients with hepatitis C, such as cryoglobulinaemia and vasculitis; additional psychological effects on quality of life due to hepatitis C and also on the treatment of children and adolescents with hepatitis C.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Warwick Evidence Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Hepatitis C -- Treatment, Ribavirin -- Effectiveness, Interferon -- Effectiveness
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	2004
Volume:	Vol.8
Number:	No.39
Status:	Peer Reviewed
Publication Status:	Published
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Royal College of Physicians of Edinburgh. Hepatitis C: a report produced by a working party of the Royal College of Physicians of Edinburgh. Edinburgh: Royal College of Physicians of Edinburgh; 1995. 2. Chief Medical Officer. Hepatitis C (HCV) and blood transfusion. Edinburgh: Scottish Home Office and Health Department; 1995. 3. Thomas HC, Weatherall DT, Ledingham J, Warrell DA. Clinical features of viral hepatitis. Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press; 1996. pp. 2061–9. 4. Poynard T, Bedossa P, Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349;825–32. 5. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:351–5. 6. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35–46. 7. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;97:2408–14. 8. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730–9. 9. McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C virus infection in the United States. In: Rizzetto M, Purcell R, Gerin J, Verne G, editors. Viral hepatitis and liver disease. Turin: Edizioni Minerva Medica; 1997. pp. 267–70. 10. Ramsay ME, Balogun MA, Collins M, Balraj V. Laboratory surveillance of hepatitis C virus infection in England and Wales: 1992 to 1996. Commun Dis Public Health 1998;1:89–94. 11. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001; 48:707–13. 12. Public Health Laboratory Service. Unlinked Anonymous HIV Prevalence Monitoring Programme – England and Wales. London: Department of Health; 1996. 13. Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999;58:127–31. 14. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863–73. 15. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051–5. 16. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferonalpha therapy. Ann Intern Med 1997;127:875–81. 17. Bayliss MS. Methods in outcomes research in hepatology: definitions and domains of quality of life. Hepatology 1999;29:3–6S. 18. Conry CC, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691–6. 19. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002;9:295–303. 20. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433–9. 21. Forton DM, Taylor-Robinson SD, Thomas HC. Reduced quality of life in hepatitis C – is it all in the head? J Hepatol 2002;36:435–8. 22. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston, MA: Health Institute, New England Medical Center; 1993. 23. Bonkovsky HL, Woolley JM. Reduction of healthrelated quality of life in chronic hepatitis C and improvement with interferon therapy.The Consensus Interferon Study Group. Hepatology 1999;29:264–70. 24. Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 1996;41:75–80S. 25. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209–12. 26. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002;36:401–7. 27. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482–6. 28. Ware JE, Bayliss MS, Mannocchia M, Davis GL, Bassaris H, Batey R, et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999;30:550–5. 29. Neary MP, Cort S, Bayliss MS, Ware JE. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19:77–86. 30. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev 2002;CD000370. 31. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an ‘à la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31:211–18. 32. Davis GL, Esteban MR, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493–9. 33. Foster GR, Chapman R. Combination treatment for hepatitis C is not being given. BMJ 2000; 321:899. 34. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4(33). 35. National Institute for Clinical Excellence. Guidance on the use of ribavirin and interferon alpha for hepatitis C. London: National Institute for Clinical Excellence; 2000. 36. Booth J, O’Grady J, Neuberger J, on behalf of the Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001;49:1–21. 37. Cramp M, Rosenburg W. Guidance on the treatment of hepatitis C incorporating the use of pegylated interferons. London: British Society for Gastroenterology; 2003. 38. Davis GL. Treatment of chronic hepatitis C. BMJ 2001;323:1141–2. 39. British Medical Association. British National Formulary. London: Royal Pharmaceutical Society of Great Britain; 2002. 40. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon -2a compared with interferon -2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433–8. 41. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65. 42. Scottish Medicines Consortium. The Scottish Medicines Consortium advises on pegylated interferon alpha-2b (ViraferonPeg). http://www.htbs.co.uk/smc/press/index.asp?did=697 (Accessed 6 May 2003.) 43. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. 10–12 June 2002. Hepatology 2003;36:S3–20. 44. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C. 10–12 June 2002. http://consensus.nih.gov/cons/116/ 091202116cdc_statement.htm (Accessed 18 November 2002). 45. Cammà C, Bruno S, Schepis F, Lo IO, Andreone P, Gramenzi AG, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C nonresponders to interferon monotherapy: a metaanalysis of individual patient data. Gut 2002;51:864–9. 46. Myers R P, Poynard T. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev 2002(4). 47. Verbaan HP, Widell HE, Bondeson TL, Lindgren SC. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin. Eur J Gastroenterol Hepatol 2002;14:627–33. 48. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998;5:187–92. 49. Gilmore I T, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, and Hopkins A. Indications, methods, and outcomes of precutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and Royal College of Physicians London. Gut 1995;36:437–41. 50. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82. 51. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452–7. 52. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395–403. 53. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–72. 54. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673–80. 55. Balogun MA, Ramsay ME, Parry JV, Donovan L, Andrews NJ, Newham JA, et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol Infect 2000;125:705–12. 56. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36:S145–51. 57. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426–32. 58. McHutchison J, Manns M, Harvey J, Albrecht JK. Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin [abstract]. J Hepatol 2001;34:2–3. 59. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–92. 60. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, et al. Peginterferon alfa-2a (40 Kd) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002;36(1):3. 61. Shobokshi O, Skakni L. Peg-IFN alfa-2a (40kDa) as a monotherapy or in combination with ribavirin significantly improve end of treatment response rate in HCV genotype 4 chronic active hepatitis (CAH) patients [abstract]. 53rd Annual Meeting on the Liver, 1–5 November 2002, Boston, MA, USA. Hepatology 2002;36:362A. 62. Shobokshi O, Serebour F, Skakni L, Tantawi A, Dinish T, Al-Quaiz M. Efficacy of pegylated (40 kDa) IFN alfa-2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia [abstract]. J Hepatol 2002;36:129. 63. Esmat GM, Abdel-Aziz FK, Abdel-Hamid MS, Ismail SA, Zalata KR, Mikhail NN.Treatment with PEG-interferon alfa-2b (PEG-IFN) plus ribavirin compared to interferon alfa-2b (IFN alfa-2b) plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4 [abstract]. 53rd Annual Meeting on the Liver, 1–5 November 2002, Boston, MA, USA. Hepatology 2002;36:364A. 64. Pockros P, Carithers R, Desmond P, Dhumeaux D, Fried M, Marcellin P. Evaluation of two doses of peginterferon alfa-2a for the treatment of chronic hepatitis C (CHC) [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001) 16–19 December 2001, Chicago, IL, USA. 65. Gebo, KA, Jenckes MW, Chander G, Torbenson MS, Ghanem KG, Herlong HF, et al. Management of chronic hepatitis C. Evidence Report/Technology Assessment No.60. Agency for Healthcare Research and Quality; 2002. www.ahrq.gov 66. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002;36:S135–44. 67. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303–13. 68. Myers RP, Abdo A, Poynard T. Pegylated interferon alfa for chronic hepatitis C (Protocol for a Cochrane Review). In The Cochrane Library (Issue 1). Oxford: Update Software; 2003. 69. Mohsen A, Easterbrook P, Taylor C, Norris S. Hepatitis C and HIV-1 coinfection. Gut 2002; 51:601–8. 70. Perronne C, Carrat F, Banisadr F, Morand P, Lunel F, Rosenthal E, et al. ANRS HC02-Ribavic: a randomized controlled trial of pegylated interferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin as primary treatment of chronic hepatitis C in HIV co-infected patient [abstract]. Hepatology 2002;36:283A. 71. Banisadr F, Carrat F, Pol S, Rosenthal E, Morand P, Lunel F, et al. Effects of HCV treatment on HIV course. Preliminary results of the ANRS HC 02-Ribavic study: a randomized, controlled trial of pegylated interferon alpha-2B with ribavirin vs interferon alpha-2b with ribavirin for the tratment of chronic HCV in HIV co-infection [abstract]. Hepatology 2002;36:585A. 72. Goelz J, Klausen G, Moll A, Schleehauf D, Prziwara D, Cordes C, Nzimegne, GA. Efficacy and tolerance of therapy in IFN-alpha/RBV and pegIFN-alpha/RBV in HIV-/HCV-coinfected IVDUs [abstract]. XIV International AIDS Barcelona, Conference, 7 July 2002. 73. Juarez A, Esteban JI, Sauleda S, Ribera E, Ocana I, Ruiz I, et al. Randomized trial of Intron A and ribavirin versus Peg-Intron and ribavirin in HIV HCV coinfected patients. Interim report on safety data [abstract]. Hepatology 2001;34:418A. 74. Shiffman M. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead in phase of the Hepatitis C Antiviral Long Term Treatment against Cirrhosis (HALT-C) trial [abstract]. Hepatology 2002;36:295A. 75. Jacobson IM, Russo MW, Brown RS, Lebovics E, Min A, Esposito S, et al. Pegylated interferon alfa- 2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. Gastroenterology 2002;122:79. 76. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002;36:S128–34. 77. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231–40. 78. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001; 285:193–9. 79. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. Cochrane Database Syst Rev 2002; CD002234. 80. San Miguel R, Guillen F, Cabases JM, Buti M. Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. Aliment Pharmacol Ther 2002; 16:1611–21. 81. Bonkovsky HL, Stefancyk D, McNeal K, Banner BF, Liu Q, Zucker GM, et al. Comparative effects of different doses of ribavirin plus interferon-alpha 2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Dig Dis Sci 2001;46:2051–9. 82. Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 1999; 31:130–4. 83. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.Combination of interferon and ribavirin in chronic hepatitis C: retreatment of nonresponders to interferon. Hepatology 2001;33:704–7. 84. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V, et al. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000;7:403–8. 85. Min AD, Jones JL, Esposito S, Lebovics E, Jacobson IM, Klion FM, et al. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J Gastroenterol 2001; 96:1143–9. 86. Puoti M, Cadeo GP, Putzolu V, Forleo MA, Barni MC, Cristini G, et al. Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Dig Liver Dis 2001;33:163–72. 87. Saracco G, Ciancio A, Olivero A, Smedile A, Roffi L, Croce G, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001;34:133–8. 88. Younossi ZM, Mullen KD, Zakko W, Hodnick S, Brand E, Barnes DS, et al. A randomized, doubleblind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. J Hepatol 2001;34:128–33. 89. Fontana RJ, Walsh J, Moyer CA, Lok ASF, Webster S, Klein S. High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon – results of a prospective, randomized, controlled trial. J Clin Gastroenterol 2002; 34:177–82. 90. Andreone P, Gramenzi A, Cursaro C, Sbolli G, Fiorino S, di Giammarino L, et al. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial. J Hepatol 1999; 30:788–93. 91. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998; 93:2445–51. 92. Pol S, Couzigou P, Bourliere M, Abergel A, Combis J, Larrey D, et al. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. J Hepatol 1999;31:1–7. 93. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha-interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol 1996;28:505–11. 94. Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E, et al. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 1998; 28:341–6. 95. Toccaceli F, Grimaldi M, Rosati S, Palazzini E, Laghi V. Ribavirin plus human leucocyte interferon alpha for the treatment of interferon resistant chronic hepatitis C: a controlled trial. Hepatol Res 1997;8:106–12. 96. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P, et al. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999;107:112–18. 97. Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, et al. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scand J Gastroenterol 1999;34:194–8. 98. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997; 4:185–91. 99. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995;23:13–15. 100. Milella M, Santantonio T, Pietromateria G, Maselli R, Casalino C, Mariano N, et al. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone. Ital J Gastroenterol Hepatol 1999;31:211–15. 101. Salmeron J, Ruiz E, Torres C, Rodriguez R, Lavin I, Quintero D, et al. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver 1999;19:275–80. 102. Bresci G, Parisi G, Bertoni M, Capria A. Highdose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alphainterferon. Dig Liver Dis 2000;32:703–7. 103. Ferenci P, Stauber R, Steindl-Munda P, Gschwantler M, Fickert P, Datz C, et al. Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Eur J Gastroenterol Hepatol 2001;13:699–705. 104. Tripi S, DiGaetano G, Soresi M, Cartabellotta F, Vassallo R, Carroccio A. Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment. Biodrugs 2000;13:299–304. 105. Cavalletto L, Chemello L, Donada C, Casarin P, Belussi F, Bernardinello E, et al. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group. J Hepatol 2000; 33:128–34. 106. Andreone P, Cursaro C, Gramenzi A, Fiorino S, di Giammarino L, Miniero R, et al. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study. Ital J Gastroenterol Hepatol 1999;31:688–94. 107. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812–17. 108. De Ledinghen V, Trimoulet P, Winnock M, Bernard PH, Bourliere M, Portal I, et al. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 2002;36:819–26. 109. Malik AH, Kumar KS, Malet PF, Ostapowicz G, Adams G, Wood M, et al. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon. Aliment Pharmacol Ther 2002;16:381–8. 110. Gaeta GB, Stornaiuolo G, Stanzione M, Ascione T, Pasquazzi C, Taliani G, et al. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. J Viral Hepat 2001;8:284–6. 111. Bacosi M, Russo F, D’innocenzo S, Santolamazza M, Miglioresi L, Ursitti A, et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 2002; 22:231–9. 112. Teuber G, Berg T, Naumann U, Raedle J, Brinkmann S, Hopf U, et al. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. J Viral Hepat 2001;8:276–83. 113. Teuber G, Berg T, Lafrenz M, Weidenbach H, Schoelmerich J, Wietzke-Braun P, et al. Randomized, controlled trial with interferon-alpha (IFN-alpha) combined with ribavirin with and without amantadine sulfate in primary IFN-alpha nonresponsive patients with chronic hepatitis C. J Hepatol 2001;34:23. 114. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000;32:630–4. 115. Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000;95:2928–35. 116. Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001; 7:339–45. 117. Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36:S57–64. 118. Herve S, Savoye G, Riachi G, Hellot MF, Goria O, Lerebours E, et al. Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 2001;13:495–500. 119. Albloushi SS, Murray FE, Callagy G, Courtney MG, O’Keane JC, Kay E. Changes in liver histopathology in women infected with hepatitis C through contaminated anti-D immunoglobulin injections in Ireland. Eur J Gastroenterol Hepatol 1998;10:69–73. 120. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986–92. 121. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36:S152–60. 122. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens- Sieberer U, Kurth BM, et al. Cost-effectiveness of peginterferon 2 b plus ribavirin versus interferon 2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425–32. 123. Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology 2002; 36:S195–200. 124. Patel R, Germer JJ, Tocci G, Visco-Comandini U, Antonucci G, Muir AJ, et al. Treatment of acute hepatitis C with interferon alfa-2b [1](multiple letters). N Engl J Med 2002;346:1091–2. 125. Patel R, Germer JJ, Tocci G, Visco-Comandini U, Antonucci G, Muir AJ, et al. Treatment of acute hepatitis C with interferon alfa-2b [1](multiple letters). N Engl J Med 2002;346:1091–2. 126. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the costeffectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855–65. 127. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253–8. 128. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088–93. 129. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318–24. 130. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003;17:687–94. 131. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002;65:110–11. 132. Wong JB, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical implications of the loss of adherence to weight-based dosing of ribavirin and peginterferon alfa-2b for chronic hepatitis C. Boston, MA: American Association for the Study of Liver Diseases; 2002. 133. Wong JB, Rosenber WM, Manns MP, McHutchison JG, Davis GL, Albrecht JK. Is peginterfon alfa-2b plus ribavirin cost-effective for treating chronic hepatitis C in the United Kingdom? Geneva: European Association for the Study of the Liver; 2003. 134. Gish R, Bzowej N, Brooks L. Treatment with pegylated interferon alfa-2b in combination with ribavirin improved health-related quality of life compared with interferon alfa-2b plus ribavirin in chronic hepatitis C. Alexandra, VA: American Association for the Study of Liver Diseases; 2002. 135. Hassanein TI, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. Treatment with 40 kDa peginterferon alfa-2a (Pegasys®) in combination with ribavirin significantly enhances quality of life compared with interferon alfa-2b plus ribavirin [abstract]. Hepatology 2001;34:243A. 136. Hassanein TI, Cooksley GE, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al. QoL benefits observed as early as week 2 with peginterferon alfa-2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV. European Association for the Study of the Liver, 37th Annual Meeting, Madrid, 15–21 April 2002. 137. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35:704–8. 138. Rasenack J, Zeuzem S, Feinman S, Heathcote E, Manns M, Yoshida E, et al. Peginterferon alpha-2a (40kD) [Pegasys®] Improves HR-QoL outcomes compared with unmodified interferon alpha-2a [Roferon®-A] In patients with chronic hepatitis C. Pharmacoeconomics 2003;21:341–9. 139. Feagan BG, Trepo C, Lindsay KL, Niederau C, Wong CJ, Weng CSW, et al. The impact of pegylated interferon alfa-2b on health-related quality of life in chronic hepatitis C patients. Hepatology 2000;32:590. 140. National Centre for Clinical Excellence. Guidance for manufacturers and sponsors. Technology Appraisals Process Series No. 5. London: NICE; 2002. 141. Drummond MF, O’Brien BJ, Stoddart G, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd ed. New York: Oxford University Press; 1997. 142. Gold M. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996. 143. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Costeffectiveness of 6 and 12 months of interferonalpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866–74. 144. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg 1998;61:238–42. 145. Wong JB. Estimating the cost-effectiveness of ribavirin and pegylated interferon alfa-2B for chronic hepatitis C. Hepatology 2000;32:1062. 146. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A costeffectiveness analysis. Ann Intern Med 2000;133:665–75. 147. Stein K, Jenkins B, Dalziel K, Horne J, Walker A, Royle P, et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002;6(31). 148. Department of Health. Hepatitis C strategy for England. London: Department of Health; 2002. 149. Seeff, L. Natural history of hepatitis C. Hepatology 1997;26(3), 21–8S. 150. Crowe J, Doyle C, Fielding JF. Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation [abstract]. Gastroenterology 1995;108:1054A. 151. Power JP, Lawlor E, Davidson F, Yap PL, Kenny WE, Whelton MJ, et al. Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 1994;344:1166–7. 152. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet 1997;350:1425–31. 153. Regan F, Hewitt P, Contreras BJ, on behalf of the TTI Study Group. Prospective investigation of transfusion transmitted infection in recipients of over 20,000 units of blood. BMJ 2000;320:403–7. 154. Harris HE, Ramsay ME, Heptonstall J, Soldan K, Eldridge KP. The HCV National Register: towards informing the natural history of hepatitis C infection in the UK. J Viral Hepat 2000;7:420–7. 155. Alter HJ, Conry CC, Melpolder J, Tan D, Van Raden M, Herion D, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26:29–33S. 156. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809–16. 157. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72. 158. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:34–8S. 159. Dienstag JL. The natural history of chronic hepatitis C and what we should do about it. Gastroenterology 1997;112:651–5. 160. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:15–20S. 161. Afdhal N, Flamm S, Imperial J, Malet PF, Tong M, Campagna J, et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that did not respond to Rebetron® therapy: a preliminary report of a randomized, multicenter study [abstract]. Gastroenterology 2001;120:1963. 162. Herrine SK, Brown R, Jr, Esposito S, Lok A, Galati JS, Bernstein DE, et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that relapsed on Rebetron™ therapy: a preliminary report of a randomized, multicenter efficacy and safety study [abstract]. Gastroenterology 2001;120:A-384. 163. Di Bisceglie A-M, Bernstein, DE, Rustgi V.-R, Gitlin N, Jeffers LJ, Simon D. Pegylated (40 kDa) interferon alfa-2A (Pegasys®) in new combination therapies: a report of a randomized, multicenter efficacy and safety study [abstract]. J Hepatol 2001;34:143. 164. Lawitz EJ, Cantu NS, Adams F, Davis M, Sperling R, Fein S, et al. Triple therapy compared to standard pegylated interferon alfa 2b plus weight based ribavirin for treatment naive patients with chronic hepatitis C: 24 week viral clearance [TRI-STAR trial] [abstract]. Gastroenterology 2002;123:74. 165. Zeuzem S, Herrmann E, Lee JH, Marinos G, Modi M, Roth WK. Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha 2a [abstract]. Hepatology 2001;34:1544. 166. Lindsay KL, McHutchison JG, Ling MH, Albrecht JK. Response to PEG-IFN alpha2b (PEG-Intron) in Blacks and Hispanics with HCV is higher than with standard IFN alpha2b (IFN) [abstract]. Hepatology 2000;32:347A. 167. Wong JB, Siebert U, Manns MP, McHutchison JG, Sroczynski G, Wasem J, et al. Cost-effectiveness of ribavirin and pegylated interferon alfa-2b for initial treatment of chronic hepatitis C [abstract]. Hepatology 2001;34:2075. 168. Buti M, Casado MA, Medina M, Fosbrook L, Esteban R. Is Peg-interferon plus Ribavirin a costeffective therapy, and if so, what is the most efficient way to use this therapy in naive patients with chronic hepatitis C? [abstract]. J Hepatol 2002;36:357. 169. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Costeffectiveness of peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C [abstract]. J Hepatol 2002;36:463. 170. Shiffman M, Pockros PJ, Reddy RK, Wright TL, Reindollar R, Fried MW, et al. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2a (PEG) vs standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C [abstract]. Gastroenterology 1999;116:A1275. 171. Neumann AU, Zeuzem S, Brunda MJ, Hoffman JH. Rapid viral response to treatment with pegylated (40kDa) interferon ALFA-2A (Pegasys™) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C (CHC) [abstract]. Hepatology 2000; 32:633. 172. Pockros PJ, Heathcote EJ, Shiffman ML, Bain VG, Zeuzem S, Rustgi VR, et al. Efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) in randomized trials of patients with chronic hepatitis C with and without cirrhosis: correlation of virologic responses with baseline liver histology and genotype [abstract]. Hepatology 2000;32:1131. 173. Sherman M, Dusheiko GM, Haeussinger D, Marinos G, Munoz-Espinoza L, Salmeron J, et al. Superior virologic response in genotype 4 chronic hepatitis C patients treated with pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with standard interferon [abstract]. Hepatology 2000; 32:754. 174. Shiffman ML, Fromm H, Mills P, Moonka DK, Fried MW, Berg C, et al. Enhanced efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with interferon alfa-2A (Roferon-A™) for chronic hepatitis C in Blacks [abstract]. Hepatology 2000;32:753. 175. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients with chronic hepatitis C treated with pegylated (40 kDa) interferon alfa-2a (Pegasys™) and interferon alfa-2a (Roferon-A®). Hepatology 2000;32:785. 176. Cooksley G, Foster G, Green J, Kleinman L, Hakim Z, Revicki D. The effect of successful antiviral therapy on health-related quality of life for patients with chronic hepatitis C and cirrhosis. Gastroenterology 2000;118. Dallas, TX: American Association for the Study of Liver Diseases. 177. Kamal SM, Peter T, Rasenack JW. PEG (40kDa) interferon alpha-2a therapy enhances HCV specific CD4+ T helper 1 responses during and after treatment [abstract]. Gastroenterology 2001; 120:A-55. 178. Heathcote EJ, Balart LA, Shiffman ML, Pockros PJ, Lee SS, Reddy KR, et al. Pegylated (40kDa) interferon alfa-2a (Pegasys™) is superior to interferon alfa-2a (Roferon-A®) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584 [abstract]. Hepatology 2000;32:246.
URI:	http://wrap.warwick.ac.uk/id/eprint/52125

Request changes to a record

Actions (login required)

View Item